ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19

Autor: Jie Zhang, Xuefeng Ma, Jie Tan, Yongning Xin, Likun Zhuang, Lizhen Chen, Mengzhen Dong, Shousheng Liu
Rok vydání: 2020
Předmět:
0301 basic medicine
Extrapulmonary organs
Pathology
TMPRSS2
Transmembrane protease serine 2
CCLE
Cancer Cell Line Encyclopedia
ALP
Alkaline phosphatase
ACE2
0302 clinical medicine
Medicine
GEO
Gene Expression Omnibus
PCI
Percutaneous coronary intervention
Respiratory system
Receptor
Liver injury
COVID-19
Coronavirus disease 2019
Kidney
CNS
Central nervous system
V-V
venous-venous
Serine Endopeptidases
GTEx
Genotype-Tissue Expression
TBIL
Total bilirubin
General Medicine
AMI
Acute myocardial infarction
MCS
Mechanical circulatory support
ICU
Intensive care unit
STEMI
ST-elevation myocardial infarction
medicine.anatomical_structure
030220 oncology & carcinogenesis
Angiotensin-converting enzyme 2
Angiotensin-Converting Enzyme 2
GGT
Gamma-glutamyltransferase
AST
Aspartate aminotransferase
Coronavirus Infections
BUN
Blood urea nitrogen
medicine.medical_specialty
ScRNA-Seq
Single-cell RNA sequencing
Pneumonia
Viral
RM1-950
Peptidyl-Dipeptidase A
AT2
Alveolar cells
TMPRSS2
Article
WHO
World Health Organization
Gene Expression Regulation
Enzymologic
Virus
Betacoronavirus
03 medical and health sciences
GI
Gastrointestinal injury
TEM
Transmission electronic microscope
Viral entry
ARDS
Acute respiratory distress syndrome
Animals
Humans
Scr
Serum creatinine
RNA
Messenger
NP
Nucleoprotein
Pandemics
ComputingMethodologies_COMPUTERGRAPHICS
Pharmacology
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
ALI
Acute liver injury
SARS-CoV-2
Clinical management
business.industry
AKI
Acute kidney injury
ALT
Alanine aminotransferase
COVID-19
ACE2
Angiotensin converting enzyme 2
medicine.disease
ALS
Artificial liver system
030104 developmental biology
Therapeutics. Pharmacology
business
Zdroj: Biomedicine & Pharmacotherapy, Vol 131, Iss, Pp 110678-(2020)
Biomedicine & Pharmacotherapy
ISSN: 0753-3322
Popis: Graphical abstract
Highlights • Expressions of ACE2 and TMPRSS2 were observed in the extrapulmonary organs. • Direct infections of SARS-CoV-2 in extrapulmonary organs were observed in patients with COVID-19. • Clinical manifestation and management for extrapulmonary organ injuries in COVID-19 should be noticed. • There might be a relationship between the infection of extrapulmonary organs and positive SARS-CoV-2 test in recovered patients.
At the end of 2019, the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Currently, it is breaking out globally and posing a serious threat to public health. The typically clinical characteristics of COVID-19 patients were fever and respiratory symptoms, and a proportion of patients were accompanied by extrapulmonary symptoms including cardiac injury, kidney injury, liver injury, digestive tract injury, and neurological symptoms. Angiotensin converting enzyme 2 (ACE2) has been proven to be a major receptor for SARS-CoV-2 and could mediate virus entry into cells. And transmembrane protease serine 2 (TMPRSS2) could cleave the spike (S) protein of SARS-CoV-2, which facilitates the fusion of SARS-CoV-2 and cellular membranes. The mRNA expressions of both ACE2 and TMPRSS2 were observed in the heart, digestive tract, liver, kidney, brain and other organs. SARS-CoV-2 may have a capacity to infect extrapulmonary organs due to the expressions of ACE2 and TMPRSS2 in the cells and tissues of these organs. It seems that there is a potential involvement of ACE2 and TMPRSS2 expressions in the virus infection of extrapulmonary organs and the manifestation of symptoms related to these organs in patients with COVID-19. Here, we revealed the expressions of ACE2 and TMPRSS2 in extrapulmonary organs, and we also summarized the clinical manifestation and the management of extrapulmonary complications in patients with COVID-19.
Databáze: OpenAIRE
Externí odkaz: